The Journal of Clinical Pharmacology · 2013 · 102 citations · 18 references
MedicinePharmacokineticsPharmacologyChemotherapyHematologic OncologyPharmacodynamicsAntibody-drug Conjugate PharmacokineticsHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyOncology PharmacologyPharmacokinetics Of Monoclonal AntibodiesAdministration Of Monoclonal AntibodiesAdverse Drug EventsAntibody-drug Conjugate AntibodiesAntibody-drug Conjugate DistributionMidazolam InfusionMidazolam UseMonoclonal Antibody InteractionsShort-term Safety Assessment
Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells. This study evaluated the CYP3A-mediated drug-drug interaction potential of brentuximab vedotin and the excretion of MMAE. Two 21-day cycles of brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) were administered to 56 patients with CD30-positive hematologic malignancies. Each patient also received either a sensitive CYP3A substrate (midazolam), an effective inducer (rifampin), or a strong inhibitor (ketoconazole). Brentuximab vedotin did not affect midazolam exposures. ADC exposures were unaffected by concomitant rifampin or ketoconazole; however, MMAE exposures were lower with rifampin and higher with ketoconazole. The short-term safety profile of brentuximab vedotin in this study was generally consistent with historic clinical observations. The most common adverse events were nausea, fatigue, diarrhea, headache, pyrexia, and neutropenia. Over a 1-week period, ∼23.5% of intact MMAE was recovered after administration of brentuximab vedotin; all other species were below the limit of quantitation. The primary excretion route is via feces (median 72% of the recovered MMAE). These results suggest that brentuximab vedotin (1.8 mg/kg) and MMAE are neither inhibitors nor inducers of CYP3A; however, MMAE is a substrate of CYP3A.
18
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Anas Younes, Nancy L. Bartlett, John P. Leonard et al. · New England Journal of Medicine · 2010 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations